Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Cyclic Altered Peptide Analogue Based on Myelin Basic Protein 87-99 Provides Lasting Prophylactic and Therapeutic Protection Against Acute Experimental Autoimmune Encephalomyelitis.

Emmanouil M, Tseveleki V, Triantafyllakou I, Nteli A, Tselios T, Probert L.

Molecules. 2018 Jan 31;23(2). pii: E304. doi: 10.3390/molecules23020304.

2.

Bioinformatically Informed Design of Synthetic Mammalian Promoters.

Roberts ML, Katsoupi P, Tseveleki V, Taoufik E.

Methods Mol Biol. 2017;1651:93-112. doi: 10.1007/978-1-4939-7223-4_8.

PMID:
28801902
3.

Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis.

Tseveleki V, Tselios T, Kanistras I, Koutsoni O, Karamita M, Vamvakas SS, Apostolopoulos V, Dotsika E, Matsoukas J, Lassmann H, Probert L.

Exp Neurol. 2015 May;267:254-67. doi: 10.1016/j.expneurol.2014.10.019. Epub 2014 Oct 30.

PMID:
25447934
4.

Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice.

Tselios T, Aggelidakis M, Tapeinou A, Tseveleki V, Kanistras I, Gatos D, Matsoukas J.

Molecules. 2014 Nov 4;19(11):17968-84. doi: 10.3390/molecules191117968.

5.

Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.

Voulgari-Kokota A, Fairless R, Karamita M, Kyrargyri V, Tseveleki V, Evangelidou M, Delorme B, Charbord P, Diem R, Probert L.

Exp Neurol. 2012 Jul;236(1):161-70. doi: 10.1016/j.expneurol.2012.04.011. Epub 2012 Apr 25.

PMID:
22561409
6.

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.

Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Lassmann H, Szymkowski DE, Probert L.

Brain. 2011 Sep;134(Pt 9):2722-35. doi: 10.1093/brain/awr203.

PMID:
21908876
7.

A role for neuronal NF-κB in suppressing neuroinflammation and promoting neuroprotection in the CNS.

Emmanouil M, Taoufik E, Tseveleki V, Vamvakas SS, Probert L.

Adv Exp Med Biol. 2011;691:575-81. doi: 10.1007/978-1-4419-6612-4_60. No abstract available.

PMID:
21153363
8.

Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changes.

Tseveleki V, Rubio R, Vamvakas SS, White J, Taoufik E, Petit E, Quackenbush J, Probert L.

Genomics. 2010 Aug;96(2):82-91. doi: 10.1016/j.ygeno.2010.04.004. Epub 2010 May 7.

9.

TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses.

Evangelidou M, Tseveleki V, Vamvakas SS, Probert L.

Immunol Cell Biol. 2010 Jul;88(5):586-95. doi: 10.1038/icb.2010.12. Epub 2010 Mar 9.

PMID:
20212506
10.

Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.

Emmanouil M, Taoufik E, Tseveleki V, Vamvakas SS, Tselios T, Karin M, Lassmann H, Probert L.

J Immunol. 2009 Dec 15;183(12):7877-89. doi: 10.4049/jimmunol.0900834.

11.

TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury.

Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6185-90. doi: 10.1073/pnas.0801447105. Epub 2008 Apr 14.

12.

Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.

Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.

Neurodegener Dis. 2008;5(1):32-7. Review.

PMID:
18075273
13.

Cellular FLIP long isoform transgenic mice overcome inherent Th2-biased immune responses to efficiently resolve Leishmania major infection.

Tseveleki V, Tsagozis P, Koutsoni O, Dotsika E, Probert L.

Int Immunol. 2007 Oct;19(10):1183-9. Epub 2007 Sep 18.

PMID:
17878261
14.

FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death.

Taoufik E, Valable S, Müller GJ, Roberts ML, Divoux D, Tinel A, Voulgari-Kokota A, Tseveleki V, Altruda F, Lassmann H, Petit E, Probert L.

J Neurosci. 2007 Jun 20;27(25):6633-46.

15.

Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.

Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L, Casaccia-Bonnefil P, Moscarello MA.

J Neurosci. 2006 Nov 1;26(44):11387-96.

16.

Cellular FLIP (long isoform) overexpression in T cells drives Th2 effector responses and promotes immunoregulation in experimental autoimmune encephalomyelitis.

Tseveleki V, Bauer J, Taoufik E, Ruan C, Leondiadis L, Haralambous S, Lassmann H, Probert L.

J Immunol. 2004 Dec 1;173(11):6619-26.

17.

Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.

Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, Probert L, Strickland S.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6698-703. Epub 2004 Apr 19.

Supplemental Content

Loading ...
Support Center